Download PDF
Thromb Haemost 2022; 122(01): 105-112
DOI: 10.1055/a-1503-3875
Blood Cells, Inflammation and Infection

COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit?—An Insight from the GeroCovid Registry

Stefano Fumagalli 
1   Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, Department of Experimental and Clinical Medicine, University of Florence and AOU Careggi, Florence, Italy
,
Caterina Trevisan
2   Geriatrics Division, Department of Medicine (DIMED), University of Padua, Padua, Italy
,
Susanna Del Signore
3   Bluecompanion ltd, London, United Kingdom
,
Giulia Pelagalli
1   Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, Department of Experimental and Clinical Medicine, University of Florence and AOU Careggi, Florence, Italy
,
Stefano Volpato
4   Section of Internal and Cardiorespiratory Medicine, Department of Medical Science, University of Ferrara, Ferrara, Italy
,
Pietro Gareri
5   Center for Cognitive Disorders and Dementia - Catanzaro Lido, ASP Catanzaro, Catanzaro, Italy
,
Enrico Mossello
1   Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, Department of Experimental and Clinical Medicine, University of Florence and AOU Careggi, Florence, Italy
,
Alba Malara
6   Scientific Committee of National Association of Third Age Residences (ANASTE) Calabria, Lamezia Terme (Catanzaro), Catanzaro, Italy
,
Fabio Monzani
7   Geriatrics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
Alessandra Coin
2   Geriatrics Division, Department of Medicine (DIMED), University of Padua, Padua, Italy
,
Giuseppe Bellelli
8   Acute Geriatric Unit, San Gerardo Hospital, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
,
Gianluca Zia
3   Bluecompanion ltd, London, United Kingdom
,
Raffaele Antonelli Incalzi
9   Unit of Geriatrics, Department of Medicine, Campus Bio Medico University and Teaching Hospital, Rome, Italy
,
for the GeroCovid Working Group › Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Introduction Atrial fibrillation (AF), the most frequent arrhythmia of older patients, associates with serious thromboembolic complications and high mortality. Coronavirus disease 2019 (COVID-19) severely affects aged subjects, determining an important prothrombotic status. The aim of this study was to evaluate mortality-related factors in older AF patients with COVID-19.

Methods Between March and June 2020, we enrolled ≥60 year-old in-hospital COVID-19 patients (n = 806) in GeroCovid, a multicenter observational study promoted by the Italian Society of Gerontology and Geriatric Medicine.

Results The prevalence of AF was 21.8%. In-hospital mortality was higher in the AF group (36.9 vs. 27.5%, p = 0.015). At admission, 51.7, 10.2, and 38.1% of AF cases were taking, respectively, oral anticoagulants (OACs), antiplatelet agents, and no antithrombotic therapy. During hospitalization, 51% patients switched to low-molecular-weight heparins. AF patients who survived were younger (81 ± 8 vs. 84 ± 7 years; p = 0.002) and had a lower CHA2DS2-VASc score (3.9 ± 1.6 vs. 4.4 ± 1.3; p = 0.02) than those who died. OAC use before (63.1 vs. 32.3%; p < 0.001) and during hospitalization (34.0 vs. 12.7%; p = 0.002) was higher among survivors. At multivariable analysis, lower age, higher self-sufficiency, less severe initial COVID-19 presentation, and the use of vitamin K antagonists (odds ratio [OR] = 0.16, 95% confidence interval [CI]: 0.03–0.84) or direct OACs (OR = 0.22, 95% CI: 0.08–0.56) at admission, or the persistence of OAC during hospitalization (OR = 0.05, 95% CI: 0.01–0.24), were associated with a lower chance of in-hospital death.

Conclusion AF is a prevalent and severe condition in older COVID-19 patients. Advanced age, dependency, and relevant clinical manifestations of disease characterized a worse prognosis. Preadmission and in-hospital anticoagulant therapies were positively associated with survival.

Keywords

atrial fibrillation - COVID-19 - DOACs - aged - oral anticoagulants

* Members of the GeroCovid Working Group are listed in [Supplementary Appendix A] (available in the online version).


Supplementary Material



Publication History

Received: 16 February 2021

Accepted: 05 May 2021

Accepted Manuscript online:
07 May 2021

Article published online:
18 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42 (05) 373-498
    CrossrefPubMedGoogle Scholar
  • 2 Fumagalli S, Potpara TS, Bjerregaard Larsen T. et al. Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. Europace 2017; 19: 1896-1902
    CrossrefPubMedGoogle Scholar
  • 3 Liles J, Liles J, Wanderling C, Syed M, Hoppensteadt D, Fareed J. Increased level of thrombotic biomarkers in patients with atrial fibrillation despite traditional and new anticoagulant therapy. Clin Appl Thromb Hemost 2016; 22 (08) 743-748
    CrossrefPubMedGoogle Scholar
  • 4 Kim D, Yang PS, Yu HT. et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J 2019; 40 (28) 2313-2323
    CrossrefPubMedGoogle Scholar
  • 5 Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc 2021; 10 (03) e019650
    CrossrefPubMedGoogle Scholar
  • 6 Gu SX, Tyagi T, Jain K. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol 2021; 18 (03) 194-209
    CrossrefPubMedGoogle Scholar
  • 7 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 8 Inciardi RM, Adamo M, Lupi L, Metra M. Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk?. Eur Heart J 2020; 41 (32) 3094
    CrossrefPubMedGoogle Scholar
  • 9 Fumagalli S, Salani B, Gabbani L, Mossello E, Ungar A. Covid-19 cases in a no-Covid-19 geriatric acute care setting. A sporadic occurrence?. Eur J Intern Med 2020; 77: 141-142
    CrossrefPubMedGoogle Scholar
  • 10 Mountantonakis SE, Saleh M, Fishbein J. et al; Northwell COVID-19 Research Consortium. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm 2021; 18 (04) 501-507
    CrossrefPubMedGoogle Scholar
  • 11 Russo V, Di Maio M, Attena E. et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol Res 2020; 159: 104965
    CrossrefPubMedGoogle Scholar
  • 12 Rivera-Caravaca JM, Núñez-Gil IJ, Vivas D. et al; HOPE COVID-19 Investigators. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. Eur J Clin Invest 2021; 51 (01) e13436
    CrossrefPubMedGoogle Scholar
  • 13 Nadkarni GN, Lala A, Bagiella E. et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (16) 1815-1826
    CrossrefPubMedGoogle Scholar
  • 14 Flam B, Wintzell V, Ludvigsson JF, Mårtensson J, Pasternak B. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med 2021; 289 (03) 411-419
    CrossrefPubMedGoogle Scholar
  • 15 Trevisan C, Del Signore S, Fumagalli S. et al; GeroCovid Working Group. Assessing the impact of COVID-19 on the health of geriatric patients: the European GeroCovid Observational Study. Eur J Intern Med 2021; 87: 29-35
    CrossrefPubMedGoogle Scholar
  • 16 WHO, Novel Coronavirus. COVID-19 Therapeutic Trial Synopsis. In: WHO. ed. WHO R&D Blueprint. Geneva: World Health Organization; 2020: 1-12
    Google Scholar
  • 17 LaValley MP. Logistic regression. Circulation 2008; 117 (18) 2395-2399
    CrossrefPubMedGoogle Scholar
  • 18 Peltzer B, Manocha KK, Ying X. et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19. J Cardiovasc Electrophysiol 2020; 31 (12) 3077-3085
    CrossrefPubMedGoogle Scholar
  • 19 Fumagalli C, Rozzini R, Vannini M. et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open 2020; 10 (09) e040729
    CrossrefPubMedGoogle Scholar
  • 20 Sacco G, Foucault G, Briere O, Annweiler C. COVID-19 in seniors: findings and lessons from mass screening in a nursing home. Maturitas 2020; 141: 46-52
    CrossrefPubMedGoogle Scholar
  • 21 Petermann-Rocha F, Hanlon P, Gray SR. et al. Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank. BMC Med 2020; 18 (01) 355
    CrossrefPubMedGoogle Scholar
  • 22 Laosa O, Pedraza L, Álvarez-Bustos A. et al. Rapid assessment at hospital admission of mortality risk from COVID-19: the role of functional status. J Am Med Dir Assoc 2020; 21: 1798.e2-1802.e2
    CrossrefPubMedGoogle Scholar
  • 23 Stone E, Kiat H, McLachlan CS. Atrial fibrillation in COVID-19: a review of possible mechanisms. FASEB J 2020; 34 (09) 11347-11354
    CrossrefPubMedGoogle Scholar
  • 24 Sanchis-Gomar F, Perez-Quilis C, Lavie CJ. Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?. Eur Heart J 2020; 41 (32) 3092-3093
    CrossrefPubMedGoogle Scholar
  • 25 de Abajo FJ, Rodríguez-Martín S, Lerma V. et al; MED-ACE2-COVID19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet 2020; 395 (10238): 1705-1714
    CrossrefPubMedGoogle Scholar
  • 26 Fumagalli S, Said SAM, Laroche C. et al; EORP-AF Investigators. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF general pilot registry (EURObservational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol 2015; 1 (04) 326-334
    CrossrefPubMedGoogle Scholar
  • 27 Fohtung RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults. J Am Geriatr Soc 2017; 65 (11) 2405-2412
    CrossrefPubMedGoogle Scholar
  • 28 Chocron R, Galand V, Cellier J. et al. Anticoagulation before hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. J Am Heart Assoc 2021; 10 (08) e018624
    CrossrefPubMedGoogle Scholar
  • 29 Pardo Sanz A, Salido Tahoces L, Ortega Pérez R, González Ferrer E, Sánchez Recalde Á, Zamorano Gómez JL. New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis. Cardiol J 2021; 28 (01) 34-40
    CrossrefPubMedGoogle Scholar
  • 30 Fumagalli S, Said SA, Laroche C. et al; EORP-AF General Pilot Registry Investigators. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. Eur Heart J Cardiovasc Pharmacother 2018; 4 (03) 172-179
    CrossrefPubMedGoogle Scholar